New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography. — MSOT-FSHD

FSHD Clinical Trial

Official title:
New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography.

Status Recruiting

Clinical Trial Summary

Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most frequent muscular dystrophies in the adulthood. Multi-spectral optoacoustic tomography (MSOT) is an innovative imaging technique able to non-invasively characterize the molecular composition of the muscle tissue. With this pilot study we will explore the performance of MSOT imaging in FSHD patients and correlate the findings with clinical and MRI data, with the final aim to identify new disease biomarkers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

FSHD
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral

Clinical Trial Details

NCT number	NCT05902884
Study type	Interventional
Source	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact	Mauro Monforte
Phone	+390630154155
Email	mauro.monforte@policlinicogemelli.it
Status	Recruiting
Phase	N/A
Start date	June 26, 2023
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05409079` - Schulze Muscular Dystrophy Ability Clinical Study	N/A
Recruiting	`NCT05272969` - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Recruiting	`NCT04635891` - Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
Recruiting	`NCT05747924` - Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD)	Phase 1/Phase 2